Insmed Inc (INSM) concluded trading on Wednesday at a closing price of $97.98, with 12.72 million shares of worth about $1.25 billion changed hands on the day. Half year performance of the stock remained positive as price took a surge of 29.95% during that period and on June 11, 2025 the price saw a gain of about 7.75%. Currently the company’s common shares owned by public are about 181.90M shares, out of which, 177.29M shares are available for trading.
Stock saw a price change of 32.96% in past 5 days and over the past one month there was a price change of 44.62%. Year-to-date (YTD), INSM shares are showing a performance of 41.92% which increased to 72.35% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $57.92 but also hit the highest price of $91.86 during that period. The average intraday trading volume for Insmed Inc shares is 2.50 million. The stock is currently trading 36.58% above its 20-day simple moving average (SMA20), while that difference is up 39.06% for SMA50 and it goes to 33.82% higher than SMA200.
Insmed Inc (NASDAQ: INSM) currently have 181.90M outstanding shares and institutions hold larger chunk of about 109.34% of that.
The stock has a current market capitalization of $17.85B and its 3Y-monthly beta is at 0.81. It has posted earnings per share of -$5.95 in the same period. It has Quick Ratio of 5.44 while making debt-to-equity ratio of 13.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INSM, volatility over the week remained 12.74% while standing at 6.04% over the month.
Stock’s fiscal year EPS is expected to rise by 6.47% while it is estimated to increase by 29.69% in next year. EPS is likely to grow at an annualized rate of 47.55% for next 5-years, compared to annual growth of -13.12% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on May 13, 2025 offering a Buy rating for the stock and assigned a target price of $105 to it. Coverage by RBC Capital Mkts stated Insmed Inc (INSM) stock as an Outperform in their note to investors on February 25, 2025, suggesting a price target of $100 for the stock. On April 23, 2024, Truist Initiated their recommendations, while on February 15, 2024, Wolfe Research Initiated their ratings for the stock with a price target of $42. Stock get an Overweight rating from Wells Fargo on December 08, 2023.
